-
Padcev (enfortumab vedotin) approved in EU for advanced urothelial carcinoma
Time of Update: 2022-05-21
Median Overall Survival (OS)The FDA expanded Padcev's indication last year to include the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy .
-
Science Immunology: Why are men more prone to cancer and often have worse outcomes?
Time of Update: 2022-05-21
Science Immunology Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancerThe study investigated differences in tumor immune responses between men and women in cancers of non-reproductive origin, finding and revealing that androgens promote CD8+ T cell depletion, which leads to faster tumor cell growth .
-
Bispecific antibody epcoritamab yields positive results in LBCL, including in patients who have failed CAR-T cell therapy
Time of Update: 2022-05-21
Biopharmaceutical companies AbbVie and Genmab today announced updated results from a Phase I/II trial evaluating the bispecific antibody epcoritamab in patients with relapsed/refractory large B-cell lymphoma (LBCL).
-
Save common cancer chemotherapy regimen abbreviation comparison table
Time of Update: 2022-05-21
In clinical work, do you often confuse the abbreviations of chemotherapy regimens?In clinical work, do you often confuse the abbreviations of chemotherapy regimens?
One, lung cancer one, lung cancer lung cancer two, breast cancer two, breast cancer breast cancer three, colorectal cancer 3.
colorectal cancercolorectal cancer 4.
Gastric cancer IV.
-
Nat Med: Bloodborne tumor mutational burden as a biomarker for atezolizumab therapy in non-small cell lung cancer
Time of Update: 2022-05-21
In a study published today in the top medical journal Nature Medicine to prospectively assess blood TMB (bTMB), researchers conducted the B-F1RST trial (NCT02848651), an open-label 2 Phase III clinical trial evaluating bTMB as a predictive biomarker for first-line atezolizumab monotherapy in locally advanced or metastatic stage IIIB-IVB non-small cell lung cancer (n=152) .
-
European Radiology: Application of radiological nomogram in preoperative differentiation of cHCC-CC and ICC
Time of Update: 2022-05-21
In conclusion, this study proposes a radiomic nomogram incorporating radiomic features and clinical factors as a noninvasive imaging tool for preoperative differentiation of cHCC-CC and IMCC .
-
Lancet Oncol: Impact of neoadjuvant chemotherapy plus nintedanib on prognosis in patients with advanced muscle-invasive bladder cancer
Time of Update: 2022-05-21
For patients with muscle-invasive bladder cancer, the addition of nintedanib to the standard chemotherapy regimen is safe, but does not significantly improve the rate of pathological complete response .
-
FDA lifts restrictions on clinical studies of Magrolimab in MDS and AML
Time of Update: 2022-05-21
S. Food and Drug Administration (FDA) has lifted the hold on clinical studies of the investigational drug magrolimab in combination with azacitidine in the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) .
-
Science Advances: Cancer cells are masters of hypnotism?
Time of Update: 2022-05-21
Recently, the study was published in Science Advances under the title: When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer .
-
European Radiology: In non-small cell lung cancer patients, we found another strong imaging prognostic marker
Time of Update: 2022-05-21
Recently, a study published in the journal European Radiology explored two new geometric variables, the normalized SUVpeak-to-centre distance (nSCD) and the normalized SUVmax obtained from pre-treatment [ 18 F]FDG PET/CT Prognostic value of distance to periphery (nSPD) and its correlation with classical metabolic parameters in NSCLC patients undergoing surgery .
-
Nature Reviews Drug Discovery: Using NK Cells for Cancer Immunotherapy
Time of Update: 2022-05-21
Bispecific or specific antibodiesBispecific or specific antibodiesBispecific or trispecific antibodies can simultaneously bind to NK cell-activated receptors and tumor antigens, promoting more potent and durable NK-mediated cytotoxicity .
-
Nature: Li Ming's team discovered a new type of T cells with stronger anti-cancer ability, bringing new hope for solid tumor immunotherapy
Time of Update: 2022-05-20
Li Ming , Zhou Jun , Zhang XuanNature This study reveals a new mechanism of immune anti-cancer In the latest study, the research team first discovered a type of innate killer T cells (Killer Innate -T cells ) that lack PD-1 but highly express the Natural Killer Cell receptor in a mouse breast cancer model (PyMT).
-
Nat Med: Scientists reveal gut microbes correlate with tumor immunotherapy response
Time of Update: 2022-05-20
The findings were published in Nat Med under the title "Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1" .
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.
-
Cardiovasc Diabetol: TyG Index as a Surrogate for Cardiovascular Risk Stratification in Cancer Survivors
Time of Update: 2022-05-20
In conclusion, the TyG index can be used as a simple surrogate for risk stratification of future cardiovascular disease events (especially atherosclerotic subtypes) in cancer survivors .
The TyG index may serve as a simple surrogate for risk stratification of future cardiovascular disease events (especially atherosclerotic subtypes) in cancer survivors .
-
Chinese Academy of Sciences Reveals: Chemotherapy Resistance Mechanisms and Overcoming Strategies for Small Cell Lung Cancer!
Time of Update: 2022-05-20
This study revealed the function and mechanism of mevalonate (MVA)-geranylgeranyl diphosphate (GGPP) metabolic pathway in chemoresistance in small cell lung cancer, and proposed a new strategy for targeted therapy .
-
BMJ: Sintilimab combined with chemotherapy as first-line therapy significantly prolongs survival in patients with advanced/metastatic esophageal squamous cell carcinoma
Time of Update: 2022-05-20
Compared with placebo plus chemotherapy, sintilimab plus chemotherapy as first-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma significantly prolongs overall survival and progression-free survival .
-
Cell Reports: Genome-wide identification and analysis of prognostic biomarkers in human cancer
Time of Update: 2022-05-20
Recently, researchers at Yale University School of Medicine published an article titled "Genome-wide identification and analysis of prognostic features in human cancers" in the journal Cell Reports, which established a rich resource for prognostic biomarker analysis.
-
Put down your burger and fries!
Time of Update: 2022-05-20
Among menopausal women, higher adherence to the WD pattern was associated with an increased risk of IDC (Model 2: OR highest vs lowest tertile: 2.
Among menopausal women, higher adherence to the WD pattern was associated with an increased risk of IDC (Model 2: OR highest vs lowest tertile: 2.
-
Update on CSCO Clinical Practice Guidelines for Tumor-Associated Anemia
Time of Update: 2022-05-20
The update and upgrade of the method is expected to benefit more patients with tumor-related anemia :Compared with the 2021 version of the guidelines , this update mainly focuses on three parts: hematopoietic malignancies, EPO ( human erythropoietin / recombinant human erythropoietin for short , the same below ) dose and dose adjustment, intravenous iron use , and treatment.
-
FDA grants priority review to Enhertu in lung cancer
Time of Update: 2022-05-20
The drug first received accelerated approval for HER2-positive unresectable or metastatic breast cancer in 2019 and FDA approval in 2021 for previously treated HER2-positive locally advanced orgastric cancer .